Tilray Expands Global Cannabis Capacity to 275 Metric Tonnes a Year

Tilray Brands has lifted its annual cannabis cultivation capacity to roughly 275 metric tonnes, up from 210 metric tonnes, through expanded output at its greenhouse in Quebec and its EU-GMP-certified facility in Portugal, the company announced on August 20, 2026. The expansion is aimed squarely at international medical cannabis demand: Tilray says the added volume will supply Europe, Australia and other regulated markets, alongside the Quebec market itself.

The Quebec facility gains 30 metric tonnes of annual capacity, and Tilray is now shipping Quebec-grown bulk cannabis directly to its sites in Portugal and Australia. The site is also on track to achieve EU-GMP certification within the next 12 months, which would put it on the same pharmaceutical-quality footing as the Portugal operation. In Portugal, the company increased output at what it describes as one of Europe’s largest medical cannabis production sites, strengthening supply to Germany, the United Kingdom and other European markets. In Germany, Tilray’s Aphria RX facility in Neumünster is fully utilized, and its new ARX brand has launched with what the company calls strong early patient response.

“Tilray is defining what global leadership in cannabis looks like,” said Irwin D. Simon, the company’s chairman and chief executive officer, in the announcement. “We are expanding production across Canada and Europe, increasing global capacity to approximately 275 metric tonnes, and strengthening the supply infrastructure needed to serve patients and partners across the world’s most important medical cannabis markets.”

Quebec Becomes an Export Origin, Not Just a Provincial Supplier

The structural change in this announcement is the role Quebec now plays inside Tilray’s supply chain. The facility (a greenhouse in Masson, Quebec, that Tilray has converted to cannabis from earlier use) was historically a domestic asset. Under the new configuration, Quebec-grown bulk flower moves directly to Tilray’s own downstream sites in Portugal and Australia, where it can be processed and packaged for pharmacy channels. That converts a single-market cultivation asset into the front end of a cross-border supply line, and it mirrors the path Canadian flower has been taking into Europe more broadly: UK medical cannabis imports doubled again in 2025, with Canadian producers dominating.

The planned EU-GMP certification for Quebec is the load-bearing piece of that design. EU-GMP, the European Union’s good manufacturing practice standard, is effectively the entry ticket for selling medical cannabis flower into European pharmacy systems. Tilray already operates GMP-certified facilities in both Portugal and Germany (Aphria RX); a certified Quebec facility would add the company’s first EU-GMP-certified production node in Canada, hedging against a bottleneck at any single site. Until certification lands, the release notes, the Quebec volume feeds markets where it qualifies and builds inventory.

The 275-metric-tonne figure continues a build-out Tilray has been staging for two years. In February 2025, the company completed Phase I of an accelerated supply-chain growth plan, bringing idled sections of its Aphria One greenhouse in Leamington, Ontario back online and putting its global capacity at approximately 247 metric tonnes, with Canadian capacity at 210. The new announcement lifts the global figure by another 28 metric tonnes and, for the first time, tilts the growth toward export-originating assets rather than Canadian domestic supply.

The Capacity Number Against the Revenue Mix

The production increase lands against a fiscal year in which international cannabis was Tilray’s fastest-growing cannabis channel. For the year ended May 31, 2026, the company reported:

• Record net revenue of $915.5 million, up 11% year over year
• Cannabis net revenue of $268.3 million, up 8%
• Revenue from international cannabis of $84.9 million, up 34% from $63.4 million
• Cannabis gross margin of 40%, unchanged year over year
• Approximately $235 million in cash, restricted cash and marketable securities, with net debt reduced to $0.7 million

International cannabis is still the smaller part of the cannabis business — Canadian adult-use generated $236.4 million in fiscal 2026 against the international channel’s $84.9 million — but it is growing roughly four times as fast, and it is the channel that carries pharmaceutical-grade pricing. The company’s own forward-looking statement frames expected annual capacity at approximately 260 to 275 metric tonnes and treats the Quebec certification timeline and the bulk-shipment plan as intentions rather than completed facts.

The commercial plumbing behind that bet has been assembled over the past year. Tilray distributes into German pharmacies through its CC Pharma subsidiary, and it has been building direct patient-access platforms: HelloMD in Canada, acquired in a court-supervised sale earlier this year, and the Lyphe clinic network in the United Kingdom, through which Tilray Medical began shipping its own flower directly to UK patients on August 17, 2026. Cultivation in Canada and Portugal, pharmaceutical distribution in Germany, and clinics in the UK and Canada now sit inside one corporate structure — 20 countries, more than 200 medical cannabis products, and, as of this announcement, approximately 275 metric tonnes of annual production capacity behind them.